ARTICLE SUMMARY:
Argá Medtech expects to join the increasingly competitive pulsed field ablation market by 2028 with its Coherent Sine-Burst Electroporation system.
Argá is enrolling atrial fibrillation (AF) patients in the pivotal trial of its Coherent Sine-Burst Electroporation (CSE) pulsed field ablation (PFA) system while continuing to develop a version of the system designed specifically to treat ventricular tachycardia.
